Targeting superbugs: comparing base editing and CRISPR-Cas in AMR control | ||
| Microbes and Infectious Diseases | ||
| Articles in Press, Accepted Manuscript, Available Online from 16 June 2025 | ||
| Document Type: Review Article | ||
| DOI: 10.21608/mid.2025.361583.2566 | ||
| Authors | ||
| Snigdha Mishra; Subhasmita Mallik; Sagarbala Dash; Jatindra Nath Mohanty* | ||
| Genetic Engineering and genomic laboratory, Department of Botany, School of Applied Sciences, Centurion University of Technology and Management, Ramachandrapur, Jatni-752050, Odisha, India | ||
| Abstract | ||
| Antimicrobial resistance (AMR) is a global health crisis, increased by multidrug-resistant ESKAPE superbug pathogen that evades conventional treatments through resistance genes. Emerging genome editing tools like CRISPR-Cas systems and base editing offer promising strategies to combat AMR by targeting bacterial genomes. CRISPR-Cas can eliminate plasmid borne and chromosomal resistance genes; though its broader use is limited by off-target effects and delivery challenges. In contrast, base editing enables precise nucleotide substitutions without double-strand breaks, minimizing genomic instability and enhancing specificity. This approach effectively inactivates resistance genes, restoring antibiotic susceptibility. Our study critically evaluates the comparative effectiveness of CRISPR-Cas and base editing in addressing AMR, with emphasis on delivery mechanisms in targeting multidrug-resistant superbugs. By analyzing recent advancements, limitations, and potential synergies between the two technologies, we provide insights into their future applications in overcoming the AMR crisis. In conclusion, both CRISPR-Cas and base editing show great potential in tackling antimicrobial resistance by precisely targeting resistance genes. Advancing delivery methods and minimizing off-target effects will be the key to their successful application in clinical and environmental settings. | ||
| Keywords | ||
| genome editing; AMR; delivery methods; combat strategies; ESKAPE pathogens | ||
|
Statistics Article View: 104 |
||
